Factors Associated With the Decision to Decline Chemotherapy in Patients With Early-stage, ER+/HER2- Breast Cancer and High-risk Scoring on Genomic Assays-Reference-Cited by-同舟云学术

Factors Associated With the Decision to Decline Chemotherapy in Patients With Early-stage, ER+/HER2- Breast Cancer and High-risk Scoring on Genomic Assays

Published:2022-06 Issue:4 Volume:22 Page:367-373
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Bilani Nadeem,El Ladki Shereen,Yaghi Marita^ORCID,Main Olivia,Jabbal Iktej S.^ORCID,Elson Leah,Bou Zerdan Maroun^ORCID,Liang Hong^ORCID,Nahleh Zeina

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. What is precision medicine?;König;Eur Respir J,2017

2. An update on breast cancer multigene prognostic tests-emergent clinical biomarkers;Vieira;Front Med,2018

3. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer;Sparano;N Engl J Med,2018

4. 70-gene signature as an aid to treatment decisions in early-stage breast cancer;Cardoso;N Engl J Med,2016

5. Refusal of recommended chemotherapy for ovarian cancer: risk factors and outcomes; a national cancer data base study;Wallace;J Natl Compr Canc Netw,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Declination of Treatment, Racial and Ethnic Disparity, and Overall Survival in US Patients With Breast Cancer;JAMA Network Open;2024-05-09

2. Disparities in Hormone Receptor-Positive Breast Cancer;Current Breast Cancer Reports;2024-02-03

3. Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer;International Journal of Environmental Research and Public Health;2023-02-07